Recent evidence from a large, randomized, controlled trial has suggested that the universal administration of iron to children in malaria-endemic areas is associated with an increase in adverse health outcomes. The purpose of this paper is to summarize the available ecologic and intervention trials related to iron and malaria in children, and to set these against current knowledge of the biology of host-pathogen interactions involving iron metabolism. We conclude that, although not fully consistent, the balance of evidence confirms that administration of iron (usually in combination with folic acid) increases the incidence of malaria when given without prophylaxis and in the absence of universal access to treatment. The mechanisms by which additional iron can benefit the parasite are far from clear. There is evidence to suggest that the apparent detrimental effect of iron supplementation may vary according to levels of antecedent iron status, the presence of hemoglobinopathies and glucose-6-phosphate dehydrogenase (G6PD) deficiency, and other host genetic variants, such as variants in haptoglobin. The effects of malaria on host iron metabolism are also reviewed and reveal that the key cause of malaria-induced anemia is a maldistribution of iron and suppression of erythropoiesis rather than an exacerbation of gross iron deficiency. We tentatively conclude that, if it is to be recommended, universal iron supplementation in malarious areas should only be considered in conjunction with some form of prophylaxis (e.g., intermittent preventive therapy [IPT]) or in the context of good health services with ready access to facilities for malaria diagnosis and treatment. An alternative approach would be to screen for anemia and target supplementation only to anemic children. With regard to treatment, there is good evidence that iron supplementation should be withheld until the treatment schedule is complete, both because iron may inhibit treatment and because the absorption of oral iron is blocked by the inflammatory response.
Introduction
Iron-deficiency anemia remains highly prevalent globally, particularly in areas of the world where malaria morbidity and mortality rates are high. The success of programs to prevent and control anemia depends on an integrated strategy to treat its underlying etiologies [1] . One of the constraints to such an approach has been the conflicting evidence from research on the relationship between iron and malaria. This persistent uncertainty is testimony to the complexity of the links between body iron status, iron supplementation, and susceptibility to malaria and other infections [2] . This paper covers five topics that together should help clarify some of these uncertainties, though our final conclusion is that significant further research will be required in order to establish a more secure evidence base for future global policy on iron administration. First, we review observational and intervention studies that have examined whether alterations in iron status affect susceptibility to malaria. Second, we summarize the effects of malaria infection on host iron metabolism. Third, we examine how the malaria parasite acquires and metabolizes iron. Fourth, we examine possible interactions between host hemoglobin variants and susceptibility to malaria infection, both in the absence and in the presence of supplemental iron. Finally, we examine the evidence that other host genetic variants in pathways involved in iron metabolism may affect the iron-malaria interaction.
Observational studies linking iron status and malaria
Early observations in famine environments described the suppression of malaria in severely malnourished populations and its recrudescence in those that subsequently consumed iron-rich diets as compared with iron-deficient diets [3] . Observational studies that followed on the effect of iron status on susceptibility to malaria in moderately malnourished populations are summarized in table 1.
These studies present a conflicting picture in which raised iron status was associated with increased [4, 5] , decreased [6] , and neutral [7] effects on the subsequent risk of malaria. Two studies point toward an increased susceptibility in individuals with high iron stores, as measured by serum ferritin levels [4, 7] , but serum ferritin is affected by the acute phase response and is significantly correlated with markers of inflammation [8] , thus making such associations particularly vulnerable to confounding. Inconsistencies between study results may also derive from differences in proportions of individuals with hemoglobinopathies, which can confound the relationship between iron status and malaria [9] .
Iron supplementation and the risk of malaria
Iron supplementation has been the most widely used approach in the public health attempts to prevent and treat anemia. Early studies of the effect of oral iron supplementation on the risk of malaria often found increases in adverse malarial outcomes in supplemented groups [10, 11] , as have studies of intramuscular [12] and parenteral [13] iron administration. More recent studies, however, largely report nonsignificant effects of iron supplementation on malaria outcomes [14] [15] [16] [17] [18] (table 2) . Three meta-analyses have also been conducted and are listed in table 3.
The trials of iron supplementation in malariaendemic areas are heterogeneous in dose, duration and timing of supplementation, age group studied, hematological and malariometric inclusion criteria, and outcomes assessed. These design differences may Birth-12 mo, subanalysis of placebo group of a trial of intramuscular iron dextran, Papua New Guinea, N = 212
Infants with Hb > 13.7 g/dL and Hb > 15.7 g/dL at birth were 2-3 times more likely to have a malaria-positive slide at 12 mo* (This population has high rates of singledeletion α-thalassemia, which causes anemia and protects against malaria and is therefore a potential confounder) Snow [7] Trans R Soc Trop Med Hyg 1991 1-8 yr, observational study of premalaria season iron status and subsequent malaria morbidity, Gambia, N = 317
Susceptibility to malaria was not correlated with preseason serum iron, serum iron-binding capacity, or serum ferritin Children who had a clinical attack of malaria with high levels of parasitemia tended to have higher mean serum ferritin levels at baseline* Incidence of clinical malaria was lower in irondeficient children (IRR = 0.7)* IRR of malaria was associated with plasma ferritin* Iron status markers were associated with malaria-specific IgGs* No difference in parasite density in patients with incident malaria between iron-deficient and non-iron-deficient groups Hb, hemoglobin; IRR, incidence-rate ratio; IgG, immunoglobulin * Significant differences, as reported by the authors. All but two studies [15, 19] have found significant positive effects on markers of iron status in those receiving iron supplementation. In the trial of van den Hombergh et al. [19] , the sample size was limited and baseline characteristics were significantly different between the supplementation and placebo groups. Chippaux et al. [15] found that anemic children who remained parasite free had increased hemoglobin levels postsupplementation, but those that subsequently developed malaria did not. The effect of supplementation on hemoglobin concentrations ranged between 0.6 and 4.9 g/dL, with the highest increase occurring in a study that combined iron supplements with antimalarial therapy [17] . Other studies have also shown an additional advantage of iron plus antimalarials as regards hemoglobin recovery [16, 18] . However, despite the hematological benefits, all of these studies found nonsignificant increases in adverse malarial outcomes in the groups that received antimalarials plus iron, including increased parasite density [16] , risk of malaria [18] , and treatment failure [17] .
Six studies found no effect of iron supplements on malaria risk [19] [20] [21] [22] [23] [24] ; of these, three included large proportions of anemic subjects (74% to 94%) [20, 21, 24] , and one included only children with hemoglobin < 5 g/dL [19] . Other studies that stratified by baseline hemoglobin levels [17, 25] found that the greatest benefits occurred in the most anemic subgroups.
Three studies found an increase in clinical malaria attacks in the iron-supplemented groups [10, 11, 25] , and a further six studies found nonsignificant increases in malaria outcomes [14] [15] [16] [17] [18] 26] . One of the striking differences between study populations with significant increases in malaria outcomes and those with nonsignificant effects is access to health care and active treatment of malaria incident cases. In fact, all but one of the trials [21] that found no effect on malaria outcomes provided access to health care facilities or active follow-up and treatment of malaria incident cases. This implies that the potential detrimental effects of iron supplementation may be curtailed by concurrent effective treatment of malaria infections. However, Verhoef et al. and Nwanyanwu et al. have shown potential treatment failure effects of combining sulfadoxine-pyrimethamine with iron in the treatment of preexisting malaria, suggesting that antimalarial therapy should precede supplementation [2, 17, 18] .
These observations are further confirmed by a large study in Zanzibar by Sazawal et al. [25] that showed increases in malaria-related morbidity and mortality in the iron-supplemented arms of a randomized, controlled trial of iron/folate and iron/folate plus zinc versus placebo (summarized in trial was investigated in more detail and consequently received more intensive diagnosis and treatment of malaria and other infections. Substudy children with iron-deficiency anemia at baseline benefited significantly from iron supplementation in that they had reduced malaria and other infection-related hospital admissions and mortality [25] .
The results of this recent study in Zanzibari children have raised new concerns about possible serious side effects of iron supplementation in populations where the etiology of anemia is not solely attributable to iron deficiency and point to the need for a deeper understanding of the complex biology of iron sequestration and redistribution between different storage and functional compartments, and of the underlying host factors that influence these processes.
Effect of malaria on iron metabolism
Erythropoietic iron requirement is met largely through recycling of senescent red blood cells through reticuloendothelial macrophages, where iron is repackaged onto transferrin for transport to the bone marrow [27] . Red blood cells are predominantly engulfed directly by reticuloendothelial macrophages; however, up to 10% of normal recycling occurs as a result of intravascular hemolysis. Hemoglobin is released and rapidly bound to haptoglobin, and the resultant complex is cleared by liver parenchymal cells or the CD163 macrophagal receptor [28] . Malaria-induced destruction of infected and noninfected red blood cells both stresses and impedes the capacity of reticuloendothelial macrophages to recycle iron back to the bone marrow. Intravascular rupture of parasitized red cells, macrophagal phagocytosis of both parasitized and unparasitized red cells, and hypersplenism all contribute to the pathophysiology of the anemia associated particularly with acute malaria.
The local epidemiology and transmission characteristics of Plasmodium falciparum, together with local drug treatment and intermittent preventive therapy (IPT) practices, influence population immunity and resultant malarial clinical presentation as well as the epidemiology of anemia in a particular setting. These factors may also influence the disturbance of iron metabolism and erythropoietic response to iron supplementation. Acute malaria is associated predominantly with a picture of fever, hemolysis, and oxidant stress, whereas dyserythropoiesis predominates in the anemia of chronic malaria in a semiimmune patient [29] . Acute malarial hemolysis represents a major stress on the homeostatic mechanisms of iron flux regulation that have evolved primarily to maintain erythroblast supply while minimizing the oxidant stress-associated effects of iron. Iron can be sequestered and trapped in reticuloendothelial macrophages as a result of both chronic and acute malaria and can present a picture of iron-deficient erythropoiesis associated with normal or increased bone marrow iron. For instance, bone marrow aspirates in 23 Thai patients with uncomplicated acute malaria (age 15 to 52 years) demonstrated malarial pigment in 22 of them. Convalescent bone marrow aspirates in 16 patients (3 to 25 days after admission) demonstrated increased iron content compared with the admission sample [30] . Five of six Gambian children (< 5 years of age) with acute malaria had elevated stainable bone marrow iron, and four of six children with chronic malaria and severe anemia (hemoglobin < 6 g/dL) had either normal or markedly increased levels of bone marrow stainable iron [31] . Eighty-six percent of Indian children and adults (N = 26) with acute and 84% of those with chronic falciparum malaria and anemia (mean hemoglobin, 5.4 g/dL; N = 38) had normal or increased bone marrow iron stores [32] . Ferrokinetic studies involving the intravenous administration of 59 Fe demonstrated low unsaturated iron-binding capacity and a rapid plasma iron disappearance time in both parasitemic and postparasitemic patients with acute and secondary (recent acute infection with persistent parasitemia) P. falciparum and P. vivax in Thai adults compared with controls [33] . Incorporation of 59 Fe into red blood cells was decreased in acute (N = 5) and secondary parasitemia (11 of 14) but found to be largely normal in the postparasitemic patients, including 3 who were restudied from the parasitemic group. Iron sequestration in acute malaria is cytokine driven (elevated tumor necrosis factor α [TNF-α], IL-1, and interferon γ [IFN-γ] and diminished IL-10), [29] probably mediated via hepcidin; however, quantifying this phenomenon, assessing how long it persists after acute malaria and in association with chronic malaria, and assessing its importance in relation to malarial anemia, malaria-associated immunosuppression, and response to iron supplementation is difficult, since there are few data. Conventional indices of iron storage (e.g., ferritin) or of tissue supply (e.g., zinc protoporphyrin, soluble transferrin receptor, transferrin saturation) are affected by inflammation [8, [34] [35] [36] , and the assessment of the iron status of young children in malarious areas with acute or chronic malaria is problematic [34] . In a holoendemic environment, ferritin and erythrocyte protoporphyrin were not affected by chronic malaria in older children [37] . These indices also do not distinguish between iron deficiency and iron sequestration.
Effect of malaria on response to iron supplementation
Malaria-induced anemia does not lead to loss of iron from the body. However, iron deficiency often coexists with malaria in areas of malaria transmission, and therapy for severe postmalarial anemia commonly assumes a component due to preexisting iron deficiency. Iron supplements are routinely prescribed both for severe malaria-associated anemia and for presumed iron-deficient anemia in a malaria-endemic environment. Few studies, however, have looked at the effect of acute malaria on the response to iron supplementation, and even fewer have addressed the effect of chronic asymptomatic malaria. More commonly, studies either have either assessed the response to supplementation of children with anemia of undefined etiology in areas of coexistent malaria, iron deficiency, and hookworm or have randomized children who were anemic after malaria to a variety of hematinics. In a study of 222 Malawian children (< 5 years of age) with anemia after acute malaria, the use of Fansidar and daily supplemental iron resulted in a significantly greater hemoglobin recovery than Fansidar alone or Fansidar and weekly iron only in those children with initial hemoglobin between 5 and 8 g/dL [17] . However, a larger proportion of the iron-treated children failed to clear their malaria. In the Gambia, 600 children (mean age, 52 months; mean hemoglobin, 9.6 g/dL) with uncomplicated falciparum malaria randomized to receive chloroquine or Fansidar as treatment and then either iron, folic acid, or placebo for 28 days [22] demonstrated a significantly better hemoglobin response with iron than with placebo or folic acid (the difference in mean hemoglobin level after 1 month was 0.7 g/dL). One hundred Tanzanian children (< 30 months of age) with severe anemia (hemoglobin < 5 g/dL) were randomized either to receive daily iron supplementation or to be controls after antimalarial treatment [19] . Among the 60 who completed the 12-week follow-up without a transfusion (30 in each group), there were no differences in hemoglobin recovery. From these studies, the role of iron supplementation in the treatment of anemia after acute malaria is unclear, and it is likely that the hemoglobin response to supplementation is influenced by both the direct inflammatory effect of malaria on iron absorption and utilization and preexistent iron deficiency, which is impossible to assess in the presence of malaria. In the Gambia, we recently compared the absorption of stable-isotope-labeled iron in children anemic as a result of iron deficiency and children anemic after acute malaria. Both groups were given 30 days of iron supplementation, and the malaria group demonstrated significantly better hemoglobin recovery despite initially significantly reduced iron absorption (Doherty et al., unpublished results). Utilization of sequestered iron is likely to be a major contributor to erythroblastic iron requirement after acute malaria.
Studies of iron supplementation of populations of anemic children in malarious areas have reported either improved hemoglobin response or decreased prevalence of severe anemia [16, 22, 38, 39] . Incorporation of antimalarial intervention arms is common. Malaria transmission characteristics, study design, use of antecedent antimalarials, differing iron supplementation doses, and differing outcome measures, as well as different prevalence rates of iron deficiency and hookworm infection, have made the assessment of factors affecting hemoglobin response to iron supplementation difficult. In particular, the effect of chronic malaria on response to supplementation in high-transmission areas is unclear, as the etiology of the anemia and the chronicity of malaria parasitemia are often undefined in study subjects. In an area of intense transmission in Tanzania in which more than 80% of children (4 to 71 months old) were parasitemic at baseline and where malaria infection was strongly associated with hemoglobin, supplementation improved the iron status and motor and language development of an iron-deficient population but not did not improve hemoglobin [21, 36, 40] . The authors concluded that factors including malarial parasitemia or ineffective erythropoiesis due to inflammatory processes in a population with high levels of infectious morbidity and inflammation might have limited erythropoiesis.
An inflammatory-mediated block to iron absorption and utilization is likely to limit the erythropoietic response to supplemental iron after acute malaria; however, it is unclear whether chronic parasitemia similarly limits the response to supplemental iron. The association of chronic malaria with anemia [39] , stainable bone marrow iron [34] , and increased cytokine levels [41] might suggest a probable effect, and the eradication of parasites has been associated with hemoglobin improvement without supplemental iron [31] .
Iron metabolism by malaria parasites
In this section we consider whether the availability of iron in the host could modulate the efficiency with which malaria parasites can establish an infection and the severity of that infection. What evidence is there to support the "nutritional immunity" hypothesis that host iron availability could limit parasite invasion or multiplication and/or the clinical sequelae of parasite infection? Support for the nutritional immunity hypothesis, first stated in the 1970s, has generally waned for the majority of pathogens [2] , but there may still be a case for obligate intracellular pathogensincluding Plasmodium spp.
It may be informative to examine the research of other scientists than those typically involved in the current debate. For example, in order for this hypothesis to be true-at least in terms of the success of parasite invasion and replication-it is a requirement that P. falciparum be dependent on host iron sources for its survival. Next, is iron deficiency ever likely to be a limiting factor in the supply of iron to the parasite? The most recent research suggests that P. falciparum does utilize iron from the host, but not from the abundant supplies available in erythrocyte hemoglobin, the heme portion of which is quickly degraded to nontoxic, but non-iron-bioavailable hemozoin or from the plasma via transferrin, but from another source, possibly an intraerythrocytic labile pool of ferrous iron [42, 43] . Interestingly, measurements of this labile ferrous iron in normal and sickled erythrocytes indicate it to be positively associated with hemoglobin concentrations and negatively associated with plasma ferritin [44] . However, other researchers have reported evidence to suggest that the degradation of heme to hemozoin is incomplete, and that 50% of heme may be degraded via an alternative pathway involving reduced glutathione and releasing bioavailable iron [45, 46] . As it has been estimated that less than 1% of heme iron would be sufficient to meet parasite iron requirements [47] , iron deficiency would never induce iron-limited growth if hemoglobin were the iron source for parasites.
Another mechanism by which iron deficiency may limit parasite growth is that proposed recently by Iyer et al. [48] , who demonstrated the inhibition of hemozoin formation from toxic free heme by the naturally occurring zinc protoporphyrin IX (ZPP) at levels likely to be encountered in anemic erythrocytes. It is interesting to note that this is thought to be the mechanism by which the quinoline antimalarials act. Furthermore, Iyer et al. demonstrated that quinolines competed for ZPP binding and prevention of hemozoin formation. It is possible that via this mechanism, moderate anemia could allow the persistence of low levels of parasitemia and therefore affect the development of exposure-related antibody repertoire and clinical immunity-with consequent effects on future malarial incidence and malaria-associated anemia. However, the evidence for such an effect in human populations is currently limited, due to the lack of longitudinal studies assessing ZPP levels and parasite prevalence and density from infancy onwards.
Another research area that has been used to support the hypothesis of decreased iron availability is that of the effects of iron chelators on parasite growth in vitro and in vivo [49, 50] . Furthermore, some antimalarial drugs, such as the antibiotic cyclines, including doxycycline, are also iron chelators. However, iron chelators may not be acting by depriving the parasite of iron. Alternative mechanisms have been suggested for some chelators, including the induction of reactive oxygen species from dissociation of iron from heme and hemozoin, as suggested for the lipophilic FR160 [51] , similar to the suggested mechanism of artemisinin [52] . Furthermore, differences between the efficacy of chelators in vitro and in vivo have been associated with differences in immune modulation [53] . This may suggest that iron status could affect malarial outcomes via direct effects on immune modulation, as suggested by Nyakeriga et al. [54] . The evidence base for the effects of current iron-chelator therapies in reducing the prevalence, density, or clinical sequelae of malaria is weak-as outlined in a recent Cochrane review of clinical trials involving the use of either desferioxamine or the orally available deferiprone [55] , in which all of the seven studies included had limitations relating to study size, relevance of study populations, and, more critically, methodological and analytical faults. However, the authors of this review concluded that the results suggested possible benefits of treatment in cerebral malaria, with a shorter recovery time from coma and decreased time to parasite clearance. The initial justification for using iron-chelator therapy in cerebral malaria was based on the premise of preventing iron-induced damage to brain cells resulting from hemolysis. Therefore, it is important to note that the possible benefits of iron-chelator therapy may not relate to limitation of iron for parasite growth and may therefore not provide evidence in support of the nutritional immunity hypothesis.
Iron, malaria, and hemoglobinopathies
How do hemoglobinopathies protect against parasite invasion or multiplication and/or clinical sequelae of parasite infection? Are these polymorphisms likely to affect the relationship between iron status or supplementation and malaria? J. B. S. Haldane is credited with first postulating heterozygote selection as an explanation for the high prevalence of the thalassemias and later other hemoglobinopathies. He suggested that the small size, reduced hemoglobin concentrations, and increased resistance to hypertonic solutions of such cells may result in decreased parasite invasion or growth. Although this hypothesis has been widely accepted for some time, it has only recently been possible to demonstrate that these mutations have been maintained by selection, mostly by malaria, but possibly also other infectious causes. However, the extent and mechanisms of protection are still debated. At least in vitro, many studies have failed to demonstrate decreased ability of parasites to invade or grow in thalassemic cells or cells containing hemoglobin S (HbS). Instead the mechanisms appear to be more complicated and possibly to vary between local conditions. The common polymorphisms involved in hemoglobin synthesis or red cell formation include sickle hemoglobin (HbS), HbC, and HbE, the α and β-thalassemias, and South Asian ovalocytosis. The geographic distribution of these varies across tropical areas and can vary extensively, even within closely related regions. Current estimates of these polymorphisms are often based on single sites and are likely to be underestimates [56] , but a figure of 27 million carriers of the main hemoglobinopathies has been proposed [56] . The carrier frequency for HbS is estimated at between 5% and 40% in populations across sub-Saharan Africa, the Middle East, and parts of South Asia. HbC is limited to parts of West and North Africa, whereas HbE is common in some parts of India and Southeast Asia, with carrier rates up to 60%. The thalassemias have the broadest geographic distribution and also the widest range of causative mutations and clinical outcomes. The carrier frequencies for the more severe range of β-thalassemias is generally lower than for the α-thalassemias, which are estimated to reach carrier frequencies of up to 20% in sub-Saharan Africa, higher in Middle Eastern and Indian populations, and up to 80% in some Pacific populations (reviewed in Williams et al. [57] , Rees et al. [58] , and Maitland et al. [59] ).
In β-thalassemias, excess α-globin chains precipitate in red cell precursors, leading to ineffective erythropoiesis and resulting in anemia in the context of increased iron absorption and iron accumulation. The clinical expression of β-thalassemia varies widely, depending on the exact genetic lesions inherited and interactions with other genetic loci, including the α and γ globin genes. β-Thalassemia trait and β-thalassemia intermediate are often asymptomatic and may not be diagnosed except for mild anemia. In α-thalassemia, the excess β-chains form stable homotetramers, which do not significantly affect erythropoiesis but cause an increased rate of hemolysis of mature cells. The degree of the deficit of α-globin chains depends on the number of α-globin genes inactivated, and unless three α-globin genes are lost, the effects are subtle and various, so that the condition will go largely undiagnosed. It might be supposed that iron supplementation could be more deleterious in populations with a high prevalence of β-thalassemia mutations because of the inability to utilize the iron, leading to increased iron availability to pathogens or iron-induced oxidant stress. Interestingly, Oppenheimer [2] reported that the increased susceptibility to malaria associated with parenteral iron in Papua New Guinean children was not apparent in single-deletion α-thalassemia compared with normal children.
In a prospective case-control study in Papua New Guinea, α-thalassemic α +homozygotes and α +heterozygotes had a greatly decreased risk of severe malaria (incidence rate ratio = 0.4 and 0.66) compared with controls [9] . Furthermore, protection was also observed for hospitalization from other infections, possibly suggesting an immune component to the protection [60] , although the reduction of severe malaria may reduce infectious sequelae by invasive bacterial disease. In apparent contrast, α-thalassemia has also been associated with an increased prevalence of uncomplicated malaria in Vanuatu, particularly in very young children with P. vivax [57] . It was suggested that increased red cell turnover in these children increased susceptibility to P. vivax [58] , resulting in cross-species immunity to P. falciparum in later life [59] . A similar finding was reported for glucose-6-phosphate dehydrogenase (G6PD) deficiency in a cohort study in Uganda, in which many other potential risk factors for malarial infection were controlled for (age, water source, use of prophylaxis, bednet usage, and proximity to mosquito breeding sites). Female heterozygotes for G6PD had a significantly increased incidence of uncomplicated malaria (IRR = 1.3, p = .03) and a trend for increased parasite densities; similar trends were seen for hemizygote males. This was different from the pattern observed for HbS heterozygotes, who had a nonsignificantly decreased incidence of uncomplicated malaria and decreased parasite densities [61] .
A mechanism that has been suggested for G6PD deficiency and that may also be applicable to sickle (HbAS) and thalassemic cells involves decreased oxidative protection (G6PD) or increased constitutive oxidative stress of these cells (HbAS α/β thalassemias), especially when infected, resulting in increased clearance of the cells from non-malaria-specific immune mechanisms, essentially the same as the normal removal of old "senescent" red cells by phagocytes [62] [63] [64] . It has been proposed that such a mechanism could prevent parasitemias from reaching critically high densities and therefore protect from severe malaria and also facilitate the development of antibody repertoires in children from the maintenance of low-grade infections in young children [65] [66] [67] . In a slight modification of this hypothesis, the increased phagocytic removal of early ring-stage infected cells-compared with schizonts and trophozoites-has been demonstrated for G6PD, β-thalassemic, and HbAS cells in vitro, but not for α-thalassemic infected cells [68] . The phagocytosis of ring compared with later stages may be advantageous, since rings contain less hemozoin, the buildup of which in monocytes has been associated with decreased function. Additionally, the reduction of the later stages of parasite development may reduce the development of severe symptoms, such as cerebral malaria, from reduced endothelial adhesion of late-stage infected red blood cells to receptors such as intracellular adhesion molecule-1 (ICAM-1).
The epidemiological evidence for a protective effect of HbAS suggests that the protective effects are greatest for severe disease (reviewed by Roberts et al. [69] ). In the most comprehensive study to date, a detailed prospective cohort in two Kenyan populations, it was reported that HbS heterozygotes had a significantly decreased risk of mild clinical malaria as assessed by active surveillance (50% decreased risk; 95% confidence interval [CI], 26% to 67%]), a 75% (95% CI, 84% to 61%) decreased risk of hospital admission for malaria, and a 90% [95% CI, 3% to 99%] decreased risk of severe malaria (severe malarial anemia, cerebral malaria, or complicated malaria) [70] . There was no effect of HbAS on the risk of asymptomatic infections or of parasite density in asymptomatic infections assessed at four cross-sectional surveys. There were significant decreases in parasite densities for all of the other categories of infection. Additionally, in this study, unlike another in western Kenya [71] , the protection was specific to malaria and did not extend to other common childhood infections, including respiratory infections, gastroenteritis, and helminth infections.
What influence the hemoglobinopathic and other polymorphisms may have on the effect of iron supplementation on malarial susceptibility is potentially dependent on the extent and mechanisms of protection from infection in the different genotypes-influences that are likely to be further complicated by differential effects according to age and malarial exposure and effects of coinheritance [72] . The coinheritance of the HbS, G6PD deficiency, and α-thalassemia deletion alleles is likely to be prevalent in sub-Saharan populations, making the study of such effects in real populations extremely difficult by requiring very large sample sizes and complex statistical modeling.
To the authors' knowledge, only two published randomized, controlled trials of iron supplementation have assessed the effects by genotype-in both cases by HbAS versus HbAA [73, 74] .
In the first trial, involving Traditional Birth Attendant-administered routine iron supplementation to multigravid Gambian pregnant women, Menendez et al. [73] reported that, although overall there were significant beneficial effects on hemoglobin and packed cell volume (PCV) and on birthweight, these effects were entirely accounted for by women with the HbAA phenotype (N = 402 vs. N = 98), whereas iron-supplemented HbAS women had lower HB, PCV, and birthweight than HbAA women receiving placebo. Furthermore, even in this relatively small study, these interactions were statistically significant (p < .01 for hematological indices at delivery, baseline measurements as a covariate; p < .03 for birthweight, maternal height included as a covariate). Overall, there was no reported increase in susceptibility to malaria, as assessed by the prevalence of peripheral malaria at late pregnancy and delivery or by placental histology. Yet iron-supplemented HbAS women had an increased prevalence of placental malaria (76% [22/29] ) compared with iron-supplemented HbAA women (53% [83/158]), placebo-treated HbAA women (59% [91/154]), or placebo-treated HbAS women (58% [19/33]). At the time of this study, IPT prophylaxis was recommended only for primigravid pregnant women in the Gambia, hence the choice of the study population. What the effects of iron supplementation might be in either primigravidae or multigravidae receiving IPTwhich is now recommended for all pregnant women in malaria-endemic countries-has not been assessed. The protection afforded by the HbAS genotype is likely to vary according to gravidity and malarial endemicity. In areas of high transmission, the majority of the increased risk is borne by primigravidae, whereas in areas of lower and highly defined seasonal transmission, the increased risk extends to a greater number of pregnancies [75] . The protective effect of HbAS is thought to be greatest in relatively nonimmune young children who have not yet developed acquired immunity by exposure to a variety of clonal variants of P. falciparum and therefore have not developed a full antibody repertoire to the variant surface antigens (VSA) expressed on the cell surfaces of parasitized red blood cells.
In the second trial, the effect of the HbAS phenotype on the response to iron supplementation in children was assessed in a subanalysis of a 2 × 2 randomized, controlled trial of iron supplementation and intermittent preventive treatment (IPT) for malaria using sulfadoxine-pyrimethamine in anemic Kenyan children (hemoglobin 7 to 10.9 g/dL) [74] . There was no reported increase in the susceptibility to clinical malaria or the prevalence of parasitemia at monthly screening associated with the iron supplementation alone or with IPT [16] , whereas IPT plus iron was the most effective in increasing hemoglobin concentrations. There were no significant statistical interactions between HbAS/ AA phenotypes and treatment group. However, there was a nonsignificant increase in the incidence rate ratio of clinical malaria in the HbAS group not receiving IPT during the 12 weeks of follow-up (IRR = 4.16; 95% CI, 0.5 to 34.6) and increased geometric mean parasite density in both groups, but by far the biggest difference was seen in the group receiving IPT (6,203 vs. 1,853, p = .08 for the interaction). The authors acknowledge that the number of clinical events was very small and that these findings would need verification in a larger study, since the number of HbAS individuals (approximately 25 to 30) in each treatment group versus approximately 100 HbAA individuals, plus the short follow-up time, means that the study was grossly underpowered to assess these outcomes. If this effect is real, then the age group studied in this trial (2 to 36 months, with 78% < 18 months) should include the most affected, although greater effects might be observed in areas of lower transmission and therefore also in a greater age range of children. The results of these two trials warrant urgent further trials or retrospective analysis of prior trials with sufficient power and detail to make firm conclusions on the effects of common polymorphisms on the response to iron supplementation, which may be expected to vary by age group and transmission intensity.
Clinical trials of IPT during infancy (IPTi) have demonstrated a reduction in the prevalence of anemia in young children in malaria-endemic areas [16, 18, 38, 76] and, in some trials, a reduction in the incidence of clinical malaria [38, 76] and morbidity and mortality in the first year of life [38, 77] . However, the effects may vary depending on the timing of dosing, choice of drug, local levels of resistance, and levels of transmission [78, 79] . On the basis of our analysis above, the impact of IPTi plus iron supplementation may be modulated by levels of hemoglobinopathies, and therefore subanalyses of these studies should be performed according to genotype wherever possible.
Interactions of polymorphisms in host iron metabolism and regulatory proteins with malaria
Polymorphisms of haptoglobin, a plasma protein that binds free hemoglobin released from lysed red blood cells, recirculating the heme portion to the bone marrow through monocyte and macrophage uptake via CD136, have also been associated with malarial outcomes, although reports are conflicting. Haptoglobin exists as three common phenotypes, Hp1-1, 1-2, and 2-2. In case-control studies in India, Sudan, Ghana, and Cameroon the Hp2-2 phenotype has been associated with protection from severe malaria and placental infection [80] [81] [82] [83] . However, two studies that have assessed associations with haptoglobin genotypes did not report any associations [84, 85] . In a cohort study in Gambian children, the Hp2-2 genotype was associated with a greater drop in hemoglobin concentrations across a malarial transmission season [65] . The authors proposed that this effect may have been mediated through an increased prevalence of asymptomatic infection observed in the Hp2-2 group, which contributed to anemia but could provide protection against severe malaria. Interestingly, similar but smaller drops in hemoglobin concentration were also observed for heterozygotes for G6PD and HbS. We are currently analyzing the effects of low-dose iron supplementation during a malarial transmission season in a similar cohort of children.
Inducible heme oxygenase (iHO-1) catalyzes the breakdown of heme to generate iron, carbon monoxide, and biliverdin and is expressed in monocytes and macrophages, among other cells. Biliverdin is subsequently degraded to bilirubin, which has potent antioxidant effects. Microsatellite polymorphisms in the number of tandem repeats in the promoter of iHO-1 have been variously associated with increased and decreased oxidant stress in various disease pathologies. However, in a case-control study of cerebral malaria patients in Myanmar, homozygotes for the short number of repeats (< 28), previously associated with higher levels of transcription of iHO-1, were significantly more likely to have cerebral malaria than uncomplicated malaria (odds ratio, 3.14; p = .008) [86] . It is not clear how this effect may be mediated, but it is possible that it results from increased levels of free iron and resulting oxidant stress. In summary, the mechanisms by which various genetic polymorphisms interact with malarial infection are still not clear. Furthermore, it is not clear how they may affect a possible relationship between iron and malaria, especially in relation to supplementation, which should be differentiated from that of iron status. The current evidence suggests that the heterozygous states of the hemoglobinopathies do not protect against malaria by a simple mechanism involving iron withholding from the pathogen. However, the effects of iron supplementation in individuals with the most common polymorphisms should be carefully evaluated, taking into account differences in transmission intensity and iron status at baseline.
Conclusions
The evidence reviewed above tends to substantiate the concerns raised by the recent Pemba trial that universal administration of iron to children in malarious areas may be associated with adverse outcomes. The mechanism by which this occurs is far from clear and merits further research to test whether other chemical forms of supplementary iron might carry less risk. There is also evidence that the risk profile will be altered by host genetic variations in hemoglobinopathies, G6PD, and genes regulating iron metabolism. However, these insights are not of great practical value, because population screening and targeted supplementation programs are not feasible in the areas where iron deficiency is most prevalent. Likewise, the evidence that anemic children are probably at low risk for any adverse outcomes associated with iron supplementation implies a need for prescreening that may not be cost-effective or logistically feasible in developing-country settings.
The evidence is fairly clear that malaria causes anemia by diverting iron away from bone marrow and erythropoiesis as part of the inflammatory response, and hence iron administration alone is not likely to be the most effective means of combating the anemia. Other therapeutic paradigms that combat the inflammation and adjust the timing of iron administration to children recovering from malaria should be researched.
We suggest that further research is still required to confirm the apparent relationships between iron status and malaria and that such studies should also focus on the underlying mechanisms of the putative interaction. This might be achieved through the establishment of a multicountry collaboration to standardize protocols both for iron-supplementation interventions and for the assessment of iron and malaria status indicators. Standardizing protocols across variations in age groups, malaria transmission patterns, and genetic distributions of hemoglobinopathies will provide the evidence for a more targeted approach to policies of prevention and treatment of anemia in malaria-endemic regions.
Until this evidence is gathered we recommend that iron supplementation in malarious areas must be accompanied by effective systems for ensuring universal rapid access to diagnosis and treatment of malaria, or by preventive therapy.
